Your browser doesn't support javascript.
loading
Update on gene fusions and the emerging clinicopathological landscape of peritoneal and pleural mesotheliomas and other neoplasms.
Benzerdjeb, N; Dartigues, P; Kepenekian, V; Damiola, F; Sequeiros, R; Galateau-Salle, F; Begueret, H; Mery, E; Damotte, D; Verriele, V; Fontaine, J; Isaac, S; Valmary-Degano, S; Villeneuve, L; Glehen, O; Scherpereel, A; Forest, F; De la Fourchardiere, A; Paindavoine, S; Hourlier, A; Pissaloux, D; Tirode, F; Lantuejoul, S.
Afiliação
  • Benzerdjeb N; Department of Pathology, Institut de Pathologie Multisite, Lyon-Sud University Hospital, Hospices Civils de Lyon, Pierre-Bénite; CICLY - EA3738, Université Claude Bernard Lyon 1, Lyon. Electronic address: nazim.benzerdjeb@chu-lyon.fr.
  • Dartigues P; Department of Pathology, Gustave Roussy Institute, Villejuif.
  • Kepenekian V; CICLY - EA3738, Université Claude Bernard Lyon 1, Lyon; Department of Digestive Surgery, CNR RENAPE, Lyon-Sud University Hospital, Lyon.
  • Damiola F; The Unit of Molecular Pathology, INSERM 1052, CNRS 5286 of Cancer Research Center of Lyon, and Team Genetics, Epigenetics and Biology of Sarcomas, Université Claude Bernard Lyon 1, Lyon; Department of Biopathology, CNR MESOPATH NETMESO, CLCC UNICANCER Leon Berard, Lyon.
  • Sequeiros R; Department of Biopathology, CNR MESOPATH NETMESO, CLCC UNICANCER Leon Berard, Lyon.
  • Galateau-Salle F; The Unit of Molecular Pathology, INSERM 1052, CNRS 5286 of Cancer Research Center of Lyon, and Team Genetics, Epigenetics and Biology of Sarcomas, Université Claude Bernard Lyon 1, Lyon.
  • Begueret H; Department of Pathology, Bordeaux University Hospital, Bordeaux.
  • Mery E; Department of Pathology, Claudius Regaud Institute, IUTC Oncopôle, Toulouse.
  • Damotte D; Department of Pathology, Centre - Paris University Hospital, Cochin Hospital, Assistance Publique - Hôpitaux de Paris, Paris; Centre de Recherche des Cordeliers, University Sorbonne, INSERM, University Paris Cité, Team Inflammation, Complement and Cancer, Paris.
  • Verriele V; Institut de Cancérologie de l'Ouest, Angers.
  • Fontaine J; Department of Pathology, Institut de Pathologie Multisite, Lyon-Sud University Hospital, Hospices Civils de Lyon, Pierre-Bénite; CICLY - EA3738, Université Claude Bernard Lyon 1, Lyon.
  • Isaac S; Department of Pathology, Institut de Pathologie Multisite, Lyon-Sud University Hospital, Hospices Civils de Lyon, Pierre-Bénite; CICLY - EA3738, Université Claude Bernard Lyon 1, Lyon.
  • Valmary-Degano S; University Grenoble Alpes, Inserm U1209, IAB, Department of Pathology, University Hospital, Grenoble.
  • Villeneuve L; CICLY - EA3738, Université Claude Bernard Lyon 1, Lyon; Department of Epidemiology and Clinical Research, Pôle de Santé Publique, Hospices Civils de Lyon, Lyon.
  • Glehen O; CICLY - EA3738, Université Claude Bernard Lyon 1, Lyon; Department of Digestive Surgery, CNR RENAPE, Lyon-Sud University Hospital, Lyon.
  • Scherpereel A; University of Lille, Thoracic Oncology Department, CNR Mesoclin NETMESO, CHU Lille CNRS, INSERM, Institut Pasteur de Lille, UMR9020-UMR-S 1277-Canther, Lille.
  • Forest F; Department of Pathology, University Hospital of Saint Etienne, Saint Etienne.
  • De la Fourchardiere A; The Unit of Molecular Pathology, INSERM 1052, CNRS 5286 of Cancer Research Center of Lyon, and Team Genetics, Epigenetics and Biology of Sarcomas, Université Claude Bernard Lyon 1, Lyon.
  • Paindavoine S; The Unit of Molecular Pathology, INSERM 1052, CNRS 5286 of Cancer Research Center of Lyon, and Team Genetics, Epigenetics and Biology of Sarcomas, Université Claude Bernard Lyon 1, Lyon.
  • Hourlier A; The Unit of Molecular Pathology, INSERM 1052, CNRS 5286 of Cancer Research Center of Lyon, and Team Genetics, Epigenetics and Biology of Sarcomas, Université Claude Bernard Lyon 1, Lyon.
  • Pissaloux D; The Unit of Molecular Pathology, INSERM 1052, CNRS 5286 of Cancer Research Center of Lyon, and Team Genetics, Epigenetics and Biology of Sarcomas, Université Claude Bernard Lyon 1, Lyon.
  • Tirode F; The Unit of Molecular Pathology, INSERM 1052, CNRS 5286 of Cancer Research Center of Lyon, and Team Genetics, Epigenetics and Biology of Sarcomas, Université Claude Bernard Lyon 1, Lyon.
  • Lantuejoul S; The Unit of Molecular Pathology, INSERM 1052, CNRS 5286 of Cancer Research Center of Lyon, and Team Genetics, Epigenetics and Biology of Sarcomas, Université Claude Bernard Lyon 1, Lyon; Department of Biopathology, CNR MESOPATH NETMESO, CLCC UNICANCER Leon Berard, Lyon; University Grenoble Alpes, Gr
ESMO Open ; 9(8): 103644, 2024 Aug.
Article em En | MEDLINE | ID: mdl-39059063
ABSTRACT

BACKGROUND:

Mesothelioma is a rare and aggressive malignant neoplasm arising from mesothelial cells, which occasionally manifests recurrent fusions. EWSR1/FUS-CREB, YY1, MAP3K8, NR4A3, and ALK-rearranged proliferations have been reported in limited series with no clear histological or clinical correlations, limiting clinicians' ability to assess prognosis and integrate these new entities into therapeutic decisions. The aim of this study was to better characterize these rearranged proliferations histologically, molecularly, and clinically.

METHODS:

Clinical, pathological, and comprehensive transcriptome and mutation data were collected for each case.

RESULTS:

A total of 41 tumors were included, encompassing 7 ALK, 10 MAP3K8, 4 NR4A3, 8 ESWR1/FUSATF1, 8 EWSR1YY1, and 4 SUFU-fused cases. We found a female predominance, except for cases harboring NR4A3 and SUFU; and most patients were around 60 years of age, but those harboring ALK or EWSR1/FUSATF1 gene fusions were younger. Each group exhibited distinct histological, immunohistochemical, molecular features, and oncological courses. Specifically, MAP3K8 and ALK presented PAX8+ papillary proliferations, ESWR1/FUSATF1 and EWSR1YY1 displayed angiomatoid fibrous histiocytoma-like patterns, while SUFU showcased 'tissue culture'-like spindle cell proliferation. Poor prognosis factors were the pleural site, male sex, Ki67 ≥10%, and ESWR1/FUSATF1 or SUFU gene fusions.

CONCLUSIONS:

This study significantly broadens the spectrum of mesothelial tumors associated with fusions, offering insight into novel epithelioid (mesothelial) proliferations with distinctive histological appearances, molecular profiles, and prognoses to guide adapted treatments for patients.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pleurais / Fusão Gênica / Mesotelioma Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pleurais / Fusão Gênica / Mesotelioma Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article